The purpose of this study is to assess the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) candidate vaccine to be administered for the first time in humans. The study intervention will be evaluated in European adults in Stage 1 (a 2-step staggered design) followed by African adults in Stage 2.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Stage 1: Number of Participants With Any Solicited Administration Site Events After the First Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)
Stage 1: Number of Participants With Any Solicited Administration Site Events After the Second Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)
Stage 1: Number of Participants With Any Solicited Administration Site Events After the Third Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)
Stage 1: Number of Participants With Any Solicited Systemic Events After the First Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)
Stage 1: Number of Participants With Any Solicited Systemic Events After the Second Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)
Stage 1: Number of Participants With Any Solicited Systemic Events After the Third Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)
Stage 1: Number of Participants With Any Unsolicited Adverse Events (AE) After the First Study Intervention Administration
Timeframe: Within 28 days post vaccination (day of administration and 27 subsequent days post-first vaccination on Day 1)
Stage 1: Number of Participants With Any Unsolicited AEs After the Second Study Intervention Administration
Timeframe: Within 28 days post vaccination (day of administration and 27 subsequent days post-second vaccination on Day 57)
Stage 1: Number of Participants With Any Unsolicited AEs After the Third Study Intervention Administration
Timeframe: Within 28 days post vaccination (day of administration and 27 subsequent days post-third vaccination on Day 169)
Stage 1: Number of Participants With Any Serious Adverse Events (SAEs)
Timeframe: From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)
Stage 1: Number of Participants With Any AEs/SAEs Leading to Withdrawal From the Study
Timeframe: From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)
Stage 1: Number of Participants With Any AEs/SAEs Leading to Withholding Further Study Intervention Administration
Timeframe: From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)
Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8
Timeframe: At Day 8 (7 days after the first study intervention administration) compared to Baseline (Day 1)
Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 64
Timeframe: At Day 64 (7 days after the second study intervention administration) compared to Baseline (Day 57)
Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176
Timeframe: At Day 176 (7 days after the third study intervention administration) compared to Baseline (Day 169)
Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 29
Timeframe: At Day 29 (28 days after the first study intervention administration) compared to Baseline (Day 1)
Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 85
Timeframe: At Day 85 (28 days after the second study intervention administration) compared to Baseline (Day 57)
Stage 1: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 197
Timeframe: At Day 197 (28 days after the third study intervention administration) compared to Baseline (Day 169)
Stage 2: Number of Participants With Any Solicited Administration Site Events After the First Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)
Stage 2: Number of Participants With Any Solicited Administration Site Events After the Second Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)
Stage 2: Number of Participants With Any Solicited Administration Site Events After the Third Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)
Stage 2: Number of Participants With Any Solicited Systemic Events After the First Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-first vaccination on Day 1)
Stage 2: Number of Participants With Solicited Systemic Events After the Second Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-second vaccination on Day 57)
Stage 2: Number of Participants With Any Solicited Systemic Events After the Third Study Intervention Administration
Timeframe: Within 7 days post vaccination (day of administration and 6 subsequent days post-third vaccination on Day 169)
Stage 2: Number of Participants With Any Unsolicited AE After the First Study Intervention Administration
Timeframe: Within 28 days post vaccination (day of administration and 27 subsequent days post-first vaccination on Day 1)
Stage 2: Number of Participants With Any Unsolicited AE After the Second Study Intervention Administration
Timeframe: Within 28 days post vaccination (day of administration and 27 subsequent days post-second vaccination on Day 57)
Stage 2: Number of Participants With Any Unsolicited AE After the Third Study Intervention Administration
Timeframe: Within 28 days post vaccination (day of administration and 27 subsequent days post-third vaccination on Day 169)
Stage 2: Number of Participants With Any SAEs
Timeframe: From first study intervention administration (Day 1) up to 28 days after the third study intervention administration (Day 197)
Stage 2: Number of Participants With Any AEs/SAEs Leading to Withdrawal From the Study
Timeframe: From first study intervention administration (Day 1) up to 28 days after the third study intervention (Day 197)
Stage 2: Number of Participants With Any AEs/SAEs Leading to Withholding Further Study Intervention Administration
Timeframe: From first study intervention administration (Day 1) up to 28 days after the third study intervention (Day 197)
Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8
Timeframe: At Day 8 (7 days after the first study intervention administration) compared to Baseline (Day 1)
Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 64
Timeframe: At Day 64 (7 days after the second study intervention administration) compared to Baseline (Day 57)
Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176
Timeframe: At Day 176 (7 days after the third study intervention administration) compared to Baseline (Day 169)
Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 29
Timeframe: At Day 29 (28 days after the first study intervention administration) compared to Baseline (Day 1)
Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 85
Timeframe: At Day 85 (28 days after the second study intervention administration) compared to Baseline (Day 57)
Stage 2: Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 197
Timeframe: At Day 197 (28 days after the third study intervention administration) compared to Baseline (Day 169)